Pulmonary Vascular Complications of Liver Disease-2

Overview

About this study

The purpose of this study is to determine if certain genes, hormones, or other factors predict the risk of developing lung vessel disease in patients with liver disease and whether they determine outcome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Chronic portal hypertension from intrinsic liver disease or portal vein disease, documented by clinical history or liver biopsy
Referral for evaluation for liver transplantation (LT) or portopulmonary hypertension (or a known diagnosis of portopulmonary hypertension)
Informed consent
Age ≥ 21 years

Exclusion Criteria

Active infection
Active or recent (< 2 weeks) gastrointestinal bleeding
Lung transplant or LT recipients
Pregnant women

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Michael Krowka, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Krowka, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials